What is the catalog number for Regorafenib?

The catalog number for Regorafenib is HY-10331.

What sizes are available for Regorafenib?

Regorafenib is available in the following size(s): 5 mg, 10 mg, 10 mM - 1 mL, 50 mg, 100 mg, 500 mg.

How many pack sizes does Regorafenib come in?

Regorafenib is available in 6 different pack sizes.

Is Regorafenib in stock?

Regorafenib is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Regorafenib?

Regorafenib is manufactured by QuantiMol.

What is the estimated delivery time for Regorafenib?

Estimated delivery time for Regorafenib is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Regorafenib?

The safety data sheet for Regorafenib is available here: http://file.medchemexpress.com/batch_PDF/HY-10331/Regorafenib-SDS-MedChemExpress.pdf.

Is there an additional fee for hazardous or dry ice shipping of this product?

Yes, if this product requires dry ice or is classed as hazardous for transport, the additional fee will be explicitly shown in your quotation before you confirm the order, so there are no surprise charges later.

How many freeze-thaw cycles can this product tolerate?

We recommend aliquoting the product upon receipt to avoid repeated freeze-thaw cycles, which can reduce activity and stability. This is your responsibility once the product has been delivered.

Is antigen retrieval required for IHC with this antibody?

Recommended antigen retrieval methods, where applicable, are listed on the datasheet under the IHC protocol section.

Regorafenib

Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity[1].

Product Specifications

CAS Number

755037-03-7

Product Name Alternative

BAY 73-4506

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; c-Kit; FGFR; PDGFR; Raf; RET; Tie; VEGFR

Type

Reference compound

Related Pathways

Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Regorafenib.html

Purity

99.93

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=C(C(C(F)(F)F)=C1)Cl)NC2=CC=C(OC3=CC(C(NC)=O)=NC=C3)C=C2F

Molecular Formula

C21H15ClF4N4O3

Molecular Weight

482.82

Precautions

H302, H315, H319, H335

References & Citations

[1]Wilhelm SM, et al. Regorafenib (BAY 73-4506) : a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer, 2011, 129 (1), 245-255.|[2]Heng DY, et al. Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. Ther Adv Med Oncol, 2010, 2 (1), 39-49.|[3]Carr BI, et al. Fluoro-Bay 43-9006 (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol, 2013, 228 (2), 292-297.|[4]Wagner J, et al. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms. J Exp Clin Cancer Res. 2018 Jan 22;37 (1) :11.|[5]Matsuoka K, et al. Effective Sequential Combined Chemotherapy with Tipiracil and Regorafenib in Human Colorectal Cancer Cells. Int J Mol Sci. 2018 Sep 25;19 (10) . pii: E2915.